Alireza Pishgahi on Attenuation of Memory Impairment After Ischemia
Alireza Pishgahi, President at Novagena, shared on LinkedIn:
”I am proud to announce that our valuable study on Stroke Regeneration have been published.
Looking forward to bring it from bench to bedside.”
Stroke is the second leading cause of death globally, placing a heavy burden on both public health and economies.
This study explored the impact of autologous conditioned serum (ACS) on memory and related molecular factors in a mouse model of ischemic stroke.
The findings suggest that intranasal ACS treatment after stroke improves memory, likely by elevating IGF-1 levels, reducing inflammation via IL-1β inhibition, and regulating tau protein levels.
Read the full article here.
Article: Intranasal Autologous Conditioned Serum Attenuates Memory Impairment After mPFC Ischemia in Mice
Authors: Sareh Kazmi, Neda Yazdanfar, Fatemehsadat Seyedaghamiri, Alireza Pishgahi, Mehdi Yousefi, Tahereh Ghadiri, Saeed Sadigh-Eteghad, Mehdi Farhoudi

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 16, 2026, 15:35Jim Hoffman: Could Blood Purification Change the Fight Against Cancer?
-
Nov 16, 2026, 15:16How Do Artificial Hearts Affect Platelet Function? – Platelets Journal
-
Nov 16, 2026, 15:10Assessing Coagulation Activation in DOAC – Treated Patients – JTH
-
Nov 16, 2026, 15:00Davide Antonio Mei: Should Anticoagulation Continue After AF Ablation?
-
Nov 16, 2026, 14:55Danielle Boyle: Beyond Platelet Counts – Why Patient Stories Matter
-
Nov 16, 2026, 14:28Jan Sloves: The Future of Vascular Ultrasound
-
Nov 16, 2026, 13:49Bahman Rasouli: A Rare Vascular Manifestation of Recurrent Papillary Thyroid Carcinoma
-
Nov 16, 2026, 13:28Muhammad Danyal: Platelet Patterns in Hepatitis B and C
-
Nov 16, 2026, 12:52Frank Nocken: Alzheimer’s Research Expands Beyond Amyloid-Based Treatments